113 related articles for article (PubMed ID: 7160922)
1. Percutaneous absorption of 5 alpha-dihydrotestosterone in man. II. Percutaneous administration of 5 alpha-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness.
Chemana D; Morville R; Fiet J; Villette JM; Tabuteau F; Brerault JL; Passa P
Int J Androl; 1982 Dec; 5(6):595-606. PubMed ID: 7160922
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous absorption of 5 alpha-dihydrotestosterone in man. I. Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5 alpha-dihydrotestosterone.
Fiet J; Morville R; Chemama D; Villette JM; Gourmel B; Brerault JL; Dreux C
Int J Androl; 1982 Dec; 5(6):586-94. PubMed ID: 6819234
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
4. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
Ghanadian R; Puah CM
J Endocrinol; 1981 Feb; 88(2):255-62. PubMed ID: 6162906
[TBL] [Abstract][Full Text] [Related]
5. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
6. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
7. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.
Skakkebaek NE; Bancroft J; Davidson DW; Warner P
Clin Endocrinol (Oxf); 1981 Jan; 14(1):49-61. PubMed ID: 7014044
[TBL] [Abstract][Full Text] [Related]
8. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
10. A study of the endocrine manifestations of hepatic cirrhosis.
Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
[TBL] [Abstract][Full Text] [Related]
11. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
Winters SJ; Atkinson L
Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
[TBL] [Abstract][Full Text] [Related]
12. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
Stuenkel CA; Dudley RE; Yen SS
J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
[TBL] [Abstract][Full Text] [Related]
13. Liver iron overload is associated with elevated SHBG concentration and moderate hypogonadotrophic hypogonadism in dysmetabolic men without genetic haemochromatosis.
Gautier A; Lainé F; Massart C; Sandret L; Piguel X; Brissot P; Balkau B; Deugnier Y; Bonnet F
Eur J Endocrinol; 2011 Aug; 165(2):339-43. PubMed ID: 21646287
[TBL] [Abstract][Full Text] [Related]
14. Androgen metabolism in men receiving finasteride before prostatectomy.
Norman RW; Coakes KE; Wright AS; Rittmaster RS
J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
[TBL] [Abstract][Full Text] [Related]
15. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis.
Diamond T; Stiel D; Posen S
J Bone Miner Res; 1991 Jan; 6(1):39-43. PubMed ID: 2048430
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS
J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
[TBL] [Abstract][Full Text] [Related]
17. Production rates of cortisol in men with hypogonadism.
Vierhapper H; Nowotny P; Waldhäusl W
Metabolism; 2004 Sep; 53(9):1174-6. PubMed ID: 15334380
[TBL] [Abstract][Full Text] [Related]
18. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
19. Hypogonadism in hemochromatosis: reversal with iron depletion.
Kelly TM; Edwards CQ; Meikle AW; Kushner JP
Ann Intern Med; 1984 Nov; 101(5):629-32. PubMed ID: 6435491
[TBL] [Abstract][Full Text] [Related]
20. [Gynecomastia: effect of prolonged treatment with dihydrotestosterone by the percutaneous route].
Kuhn JM; Laudat MH; Roca R; Dugue MA; Luton JP; Bricaire H
Presse Med; 1983 Jan; 12(1):21-5. PubMed ID: 6220269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
